Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.
β2-AGONISTS IN CHILDHOOD ASTHMA
Vol 29, Issue 2S1, 2015
Abstract
β2-agonists reduce airflow limitation by improving airway diameter as a consequence of a direct action on airway smooth muscle. β2-agonists can be broadly classified according to their duration of action: short-acting β2-agonists (SABAs), including albuterol, terbutaline and fenoterol, have pharmacodynamics half-lives between 2 and 6 h and long-acting β2-agonists (LABAs), including salmeterol and formoterol, require twice daily treatment. SABAs are often used "as needed" for asthma exacerbations and before exercise in the presence of exercise-induced bronchospasm. LABAs provide longer symptom control, which is a particularly useful feature for preventing night-time symptoms. There are two main LABAs, salmeterol and formoterol. This review focused on the recent data published on this topic.
Keywords
References
Supporting Agencies
Copyright (c) 2015 M Miraglia Del Giudice, G Campana, F Galdo, D De Vivo, C Cuppari, A Coronella, N Maiello
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Medical Genetics, University of Torino Medical School, Italy
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy